In addition, eIF4A inhibitors may also have a greater therapeutic index than BH3 mimetics because they target the enhanced translation of BCL-2 family proteins in tumor cells rather than the biological activity of these proteins in all cells. This evidence concerns the gene EIF4A1 and neoplasm.